Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | TPMT | P51580 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | RXRA | P19793 | 2/20 | 0.47 |
| ▸ | RXRB | P28702 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | EP300 | Q09472 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2543398 | 0.86 | KMT2A (0.55) | KMT2ACA12CA1CA2CA4 | |
| SCHEMBL10101882 | 0.86 | ALDH1A1 (0.54) | KMT2ATSHRALDH1A1RAB9AHTT | |
| SCHEMBL27615575 | 0.86 | CA12 (0.50) | KMT2ACA12CA1CA2CA4 | |
| SCHEMBL3545163 | 0.85 | KMT2A (0.58) | KMT2ACA12CA1CA2CA4 | |
| SCHEMBL23606802 | 0.84 | PARP10 (0.56) | KMT2ATSHRALDH1A1TDP1MAPK1 | |
| Hydrochloric Acid SCHEMBL2536673 | 0.84 | KMT2A (0.53) | KMT2ACA12CA1CA2CA4 | |
| SCHEMBL14314440 | 0.84 | CA12 (0.49) | KMT2ACA12CA1CA2CA4 | |
| SCHEMBL2827824 | 0.83 | NOTUM (0.56) | KMT2ACA12CA1CA2CA7 | |
| SCHEMBL27671948 | 0.83 | CA12 (0.51) | KMT2ACA12CA1CA2CA4 | |
| SCHEMBL23739274 | 0.83 | CA12 (0.56) | KMT2ACA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230137956-A1 | ALPHA SUBSTITUTED STAT INHIBITORS AND COMPOSITIONS THEREOF | OXFORD FINANCE LLC | 2023-05-04 | — | — | US | disclosed |
| WO-2021178907-A1 | STAT INHIBITORY COMPOUNDS AND COMPOSITIONS | JANPIX, LTD. (US) | 2021-09-10 | — | — | WO | disclosed |
| WO-2021178857-A1 | ALPHA SUBSTITUTED STAT INHIBITORS AND COMPOSITIONS THEREOF | JANPIX, LTD. (US) | 2021-09-10 | — | — | WO | disclosed |
| EP-1882684-B1 | PYRROLIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2014-12-10 | — | — | EP | disclosed |
| CN-101522645-B | Phenyl derivatives and their use as immunomodulators | ACTELION PHARMACEUTICALS LTD | 2013-01-09 | — | — | CN | disclosed |
| EP-2069318-B1 | PHENYL DERIVATIVES AND THEIR USE AS IMMUNOMODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-09-12 | — | — | EP | disclosed |
| US-8044076-B2 | Phenyl derivatives and their use as immunomodulators | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-10-25 | — | — | US | disclosed |
| US-8044076-B2 | Phenyl derivatives and their use as immunomodulators | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-10-25 | — | — | US | disclosed |
| US-8044076-B2 | Phenyl derivatives and their use as immunomodulators | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-10-25 | — | — | US | disclosed |
| US-20100087495-A1 | PHENYL DERIVATIVES AND THEIR USE AS IMMUNOMODULATORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-04-08 | — | — | US | disclosed |
| US-20100087495-A1 | PHENYL DERIVATIVES AND THEIR USE AS IMMUNOMODULATORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-04-08 | — | — | US | disclosed |
| US-7585886-B2 | Pyrrolidine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2009-09-08 | — | — | US | disclosed |
| US-7585886-B2 | Pyrrolidine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2009-09-08 | — | — | US | disclosed |
| CN-101522645-A | Phenyl derivatives and their use as immunomodulators | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-02 | — | — | CN | disclosed |
| EP-2069318-A1 | PHENYL DERIVATIVES AND THEIR USE AS IMMUNOMODULATORS | Actelion Pharmaceuticals Ltd. (CH) | 2009-06-17 | — | — | EP | disclosed |
| US-20090062366-A1 | Pyrrolidine derivative or salt thereof | ASTELLAS PHARAMA INC. (JP) | 2009-03-05 | — | — | US | disclosed |
| US-20090062366-A1 | Pyrrolidine derivative or salt thereof | ASTELLAS PHARAMA INC. (JP) | 2009-03-05 | — | — | US | disclosed |
| WO-2008035239-A1 | PHENYL DERIVATIVES AND THEIR USE AS IMMUNOMODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-27 | — | — | WO | disclosed |
| WO-2008035239-A1 | PHENYL DERIVATIVES AND THEIR USE AS IMMUNOMODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-27 | — | — | WO | disclosed |
| EP-1882684-A1 | PYRROLIDINE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062366-A1 | Pyrrolidine derivative or salt thereof | CASR, CYP2R1, PTH1R | KMT2A 3375/4885CA12 3834/4885CA1 2553/4885 |
| US-20230137956-A1 | ALPHA SUBSTITUTED STAT INHIBITORS AND COMPOSITIONS THEREOF | STAT5A, STAT5B, STAT3 | KMT2A 1902/4885CA12 4481/4885CA1 4041/4885 |
| US-20100087495-A1 | PHENYL DERIVATIVES AND THEIR USE AS IMMUNOMODULATORS | IL2, CD47, CD74 | KMT2A 2793/4885CA12 4671/4885CA1 4855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.